|Animas OneTouch® Ping®||Animas Vibe™||MiniMed™ 630G system||MiniMed™ 670G system|
|Medtronic MiniMed™ Pump Features|
|Automated basal (background) insulin delivery based on CGM readings to maximize time in range*,#|
|Ability to suspend insulin before lows occur#|
|Ability to suspend insulin when lows occur§|
|Shared Pump Features|
|Built-in continuous glucose monitoring (CGM) that communicates with the pump||
|Ability to give an insulin bolus from a wireless meter|
|Bright color screen|
|Animas Pump Features|
|Smaller, 200u reservoir|
|CalorieKing® Food Database|
The MiniMed™ 670G system offers SmartGuard technology with two new levels of automated insulin delivery — the Auto Mode and Suspend before low features.
SmartGuard™ Auto Mode‡
Smartguard™ Suspend before low§
If your pump warranty has already expired or is set to expire soon, you’re at risk of going off therapy should something happen to your Animas pump.
If your warranty expires on or after September 30, 2019, Animas has arranged the option for you to transition to a Medtronic pump at no cost. We will begin to offer this option to eligible customers starting in May 2018 to enable plenty of time for the transition.
Customers who choose not to transition to a Medtronic pump under this program can continue to use their Animas pump and should be aware that effective September 30, 2019, Medtronic will no longer be able to supply Animas cartridges or customer support for Animas pumps, so you may want to consider alternative therapy options.
If you do not wish to wait for your warranty to expire or for May 2018 to learn more about your options, Medtronic offers an in-warranty upgrade program called Switch2System. More info can be found here or by calling 1-855-322-9568.
Whether you’re an Animas® Vibe® or Animas® Ping® customer, rest assured you can now order your infusion sets, cartridges, and other supplies directly through the Medtronic Store.
Finding your diabetes-related supplies and accessories just got easier thanks to the all-new Diabetes.Shop. Check it out today!
Animas decided to close their insulin pump business in the U.S. and Canada and selected Medtronic as the company’s partner-of-choice to provide customer support through the transition. Medtronic was selected because of our rich 30-year history of innovation and service. Medtronic has supported over 1.2 million people living with diabetes around the world. Medtronic customers have access to 24-hour technical product support, supply reorder services, and dedicated global customer support. Our unparalleled service is the #1 reason that people with diabetes stay with Medtronic.
Our first priority is to ensure there is no therapy disruption for Animas customers given the significant benefits insulin pump therapy provides.
We anticipate no changes to your insurance coverage, but due to the individual nature of insurance plans, we will be able to confirm your coverage once you begin ordering supplies from Medtronic or its affiliates.
In-warranty Animas patients with a warranty that extends beyond September 30, 2019, have the option to receive a new MiniMed™ system for the remainder of their warranty period. Animas has arranged for this transition option to occur at no cost to the patient to ensure continuity of therapy
Medtronic will start to offer this transition option to eligible customers starting in Summer 2018.
Customers who choose not to transition to a Medtronic insulin pump under this program can continue to use their Animas insulin pump, but Medtronic will not be able to supply Animas cartridges and customer support will no longer be provided for Animas pumps after September 30, 2019.
We make it easy for our customers to stay connected with us and others in the Diabetes Online Community. Through our social channels, we share helpful diabetes tips, stories and perspectives from the community as well as from our Medtronic team. We count on our robust online community to give us feedback and help shape the solutions we innovate to help transform diabetes care so we invite you to join the conversation and stay connected with us!
1. Bergenstal R, Garg S, Weinzimer S, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407–1408.
2. dQ&A. (2017) dQ&A Patient Panel, Q4 2016, Summary Report.
* Refers to SmartGuard Auto Mode feature; The MiniMed® 670G system can automatically increase or decrease insulin delivery based on continuous glucose monitoring (CGM) values; however, the user must still administer meal boluses. ADA recommendation for a glucose range is 80-180 mg/dL in non-pregnant adults with diabetes. Individual results may vary. WARNING: Do not use Auto Mode for a period of time after giving a manual injection of insulin by syringe or pen. Manual injections are not accounted for in Auto Mode. Therefore, Auto Mode could deliver too much insulin. Too much insulin may cause hypoglycemia. Consult with your healthcare professional for how long you need to wait after a manual injection of insulin before you resume Auto Mode.
# Based on GuardianTM Sensor 3 glucose values.
§ WARNING: Do not use the Suspend on low feature to prevent or treat low glucose. Always confirm your sensor glucose reading using your BG meter, and follow the instructions of your healthcare professional to treat low glucose. Using Suspend on low alone to prevent or treat low glucose may result in prolonged hypoglycemia.
† The pump is protected against the effects of continuous immersion in up to 12 feet (3.6 meters) of water for up to 24 hours at a time at the time of manufacture. This is classified as IPX8 rating. See user guide for more details.
Important Safety Information: MiniMed™ 630G System with SmartGuard™ technology
The MiniMed 630G system with SmartGuard™ technology requires a prescription. It is intended for continuous delivery of basal insulin and administration of insulin boluses for the management of diabetes mellitus in persons 16 years of age or older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The SmartGuard feature allows one to program the pump to temporarily suspend delivery of insulin for up to two hours when the sensor glucose value falls below a predefined threshold value. The MiniMed 630G system is not intended to be used directly for making therapy adjustments or preventing or treating hypoglycemia. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare professional. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter (BGM). A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 Meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. Do not calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always’ send mode. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day, or who are unwilling or unable to maintain contact with their healthcare professional, or whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use U100 rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately.
WARNING: The SmartGuard Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set limit. Under some conditions of use the pump can suspend again resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard Suspend on low feature, it is important to read the SmartGuard Suspend on low information in the Getting Started Guide and the MiniMed 630G System User Guide and discuss proper use of the SmartGuard Suspend on low feature with your healthcare professional.
Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected.
Important Safety Information: MiniMed™ 670G System
The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Only use rapid acting U100 insulin with this system. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed 670G system has not been studied in pregnant women. For complete details, including product and important safety information concerning the system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.
MiniMed is a registered trademark and SmartGuard is a trademark of Medtronic, MiniMed Inc.